FRZB and myelodysplastic syndrome: Bhagat et al. found that an antagonist of the pathway—the Frizzled Related Protein (FRZB) gene—was hypermethylated, and therefore its expression was suppressed in the stromal cells of MDS patients, allowing increased activation of the Wnt pathway.